KYTXKyverna Therapeutics, Inc.

Nasdaq kyvernatx.com


$ 7.40 $ -0.21 (-2.76 %)    

Wednesday, 26-Jun-2024 15:23:00 EDT
QQQ $ 479.04 $ -0.56 (-0.12 %)
DIA $ 391.23 $ 1.12 (0.29 %)
SPY $ 544.56 $ 0.96 (0.18 %)
TLT $ 93.20 $ -0.36 (-0.38 %)
GLD $ 212.53 $ -1.66 (-0.78 %)
$ 7.74
$ 7.61
$ 7.39 x 100
$ 0.00 x 0
$ 7.11 - $ 7.61
$ 6.75 - $ 35.06
582,698
na
183.86M
$ -0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a dev...

Core News & Articles

Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option aft...

 why-kyverna-therapeutics-stock-is-sinking

Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. ...

Core News & Articles

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate o...

Core News & Articles

Financial Results for the Year Ended December 31, 2023For the year ended December 31, 2023, the company reported a net loss of ...

Core News & Articles

The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti C...

Core News & Articles

JP Morgan initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight rating and announces Price Target of $39.

Core News & Articles

Morgan Stanley analyst Michael Ulz initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight rating and ann...